In a 3-month study of 302 patients with mild stable heart failure, all of whom were receiving standard therapy for stable heart failure, addition of aliskiren 150 mg was well tolerated.
3- kuulises uuringus, kus 302 kergelt stabiilse südamepuudulikkusega patsienti, kes said stabiilse südamepuudulikkuse standardravi, oli 150 mg aliskireeni lisamine hästi talutav.